Calton & Associates, Inc. Global Blood Therapeutics, Inc. Transaction History

Calton & Associates, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 31, 2022	BUY	$32.4 - $68.18 $194,918 - $410,170	6,016 New	6,016 $409,000
Q2 2022 Jul 12, 2022	SELL	$22.3 - $37.39 $140,958 - $236,342	-6,321 Closed	0 $0
Q1 2022 Apr 12, 2022	SELL	$25.68 - $35.59 $105,210 - $145,812	-4,097 Reduced 39.33%	6,321 $218,000
Q4 2021 Jan 13, 2022	SELL	$24.9 - $40.26 $56,722 - $91,712	-2,278 Reduced 17.94%	10,418 $304,000
Q3 2021 Nov 05, 2021	BUY	$25.48 - $37.34 $168,422 - $246,817	6,610 Added 108.61%	12,696 $323,000
Q2 2021 Aug 11, 2021	SELL	$32.46 - $43.42 $3,310 - $4,428	-102 Reduced 1.65%	6,086 $219,000
Q1 2021 May 03, 2021	SELL	$38.94 - $50.85 $3,894 - $5,085	-100 Reduced 1.59%	6,188 $252,000
Q4 2020 Jan 25, 2021	BUY	$37.65 - $63.77 $22,326 - $37,815	593 Added 10.41%	6,288 $272,000
Q3 2020 Oct 30, 2020	BUY	$52.76 - $74.49 $13,981 - $19,739	265 Added 4.88%	5,695 $314,000
Q2 2020 Aug 10, 2020	SELL	$48.73 - $81.82 $243 - $409	-5 Reduced 0.09%	5,430 $343,000
Q1 2020 Apr 30, 2020	BUY	$41.72 - $87.2 $101,337 - $211,808	2,429 Added 80.81%	5,435 $278,000
Q4 2019 Feb 03, 2020	BUY	$45.7 - $81.86 $137,374 - $246,071	3,006 New	3,006 $239,000

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Calton & Associates, Inc., based on Form 13F filings with the SEC.

Stay updated on Calton & Associates, Inc. with notifications on news.